EHA 2026: LB2501 Advances In Vivo CAR-T with Single-Infusion Treatment

Lei Fang, MD, PhD, attending doctor at Jiangsu Province Hospital, presents late-breaking Phase 1 data on LB2501, a third-generation in vivo CAR-T approach designed to generate CAR-T cells directly in the patient following a single intravenous infusion without lymphodepleting chemotherapy. The presentation discusses early efficacy and safety findings and highlights how in vivo CAR-T may support a shift from personalised cellular products towards standardised gene-based medicine.